EHF
MCID: EBL001
MIFTS: 49

Ebola Hemorrhagic Fever (EHF)

Categories: Infectious diseases, Oral diseases, Rare diseases

Aliases & Classifications for Ebola Hemorrhagic Fever

MalaCards integrated aliases for Ebola Hemorrhagic Fever:

Name: Ebola Hemorrhagic Fever 12 60 15 17
Ebola Virus Disease 12 77 54 60 3
Hemorrhagic Fever, Ebola 45 74
Ebola Fever 60
Ehf 60

Characteristics:

Orphanet epidemiological data:

60
ebola hemorrhagic fever
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 60  
Rare infectious diseases


Summaries for Ebola Hemorrhagic Fever

Disease Ontology : 12 A viral infectious disease that is a hemorrhagic fever, has material basis in Zaire ebolavirus, has material basis in Sudan ebolavirus, has material basis in Cote d'Ivoire ebolavirus, or has material basis in Bundibugyo ebolavirus, which are transmitted by contact with the body fluids of an infected animal or person, transmitted by contaminated fomites, or transmitted by infected medical equipment. The infection has symptom fever, has symptom headache, has symptom joint pain, has symptom muscle aches, has symptom sore throat, has symptom weakness, has symptom diarrhea, has symptom vomiting, has symptom stomach pain, has symptom rash, has symptom red eyes, has symptom hiccups, and has symptom internal and external bleeding.

MalaCards based summary : Ebola Hemorrhagic Fever, also known as ebola virus disease, is related to stomatitis and marburg hemorrhagic fever, and has symptoms including fever and pruritus. An important gene associated with Ebola Hemorrhagic Fever is F5 (Coagulation Factor V). The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include testes, eye and liver, and related phenotypes are fatigue and recurrent pharyngitis

Wikipedia : 77 Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF) or simply Ebola, is a viral... more...

Related Diseases for Ebola Hemorrhagic Fever

Diseases related to Ebola Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 49)
# Related Disease Score Top Affiliating Genes
1 stomatitis 29.5 BST2 DDX58
2 marburg hemorrhagic fever 11.2
3 leprosy 3 11.1
4 allergic urticaria 11.1
5 neurodermatitis 11.1
6 hemorrhagic fever 11.0
7 malaria 10.3
8 endometriosis 10.2
9 migraine with or without aura 1 10.2
10 headache 10.2
11 lassa fever 10.2
12 esterase c 10.1
13 gastric cancer 10.1
14 breast cancer 10.1
15 renal oncocytoma 10.1
16 chronic interstitial cystitis 10.1
17 uveitis 10.1
18 cholera 10.1
19 mucormycosis 10.0
20 venezuelan equine encephalitis 10.0
21 encephalitis 10.0
22 ige responsiveness, atopic 10.0
23 ovarian cancer 10.0
24 ovarian cancer 1 10.0
25 pancreatic ductal adenocarcinoma 10.0
26 oral squamous cell carcinoma 10.0
27 squamous cell carcinoma 10.0
28 adenocarcinoma 10.0
29 lung disease 10.0
30 smith-magenis syndrome 9.9
31 dengue virus 9.9
32 melioidosis 9.9
33 myoclonic-atonic epilepsy 9.9
34 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 9.9
35 hemophagocytic lymphohistiocytosis 9.9
36 meningoencephalitis 9.9
37 pertussis 9.9
38 rabies 9.9
39 hemopericardium 9.9
40 pericardial effusion 9.9
41 diarrhea 9.9
42 disease of mental health 9.9
43 pneumonia 9.9
44 myocarditis 9.9
45 acute respiratory distress syndrome 9.9
46 disseminated intravascular coagulation 9.9 F5 MB
47 argentine hemorrhagic fever 9.8 DDX58 GP2
48 chikungunya 9.8 BST2 DDX58
49 coronary artery anomaly 9.7 F5 MB

Graphical network of the top 20 diseases related to Ebola Hemorrhagic Fever:



Diseases related to Ebola Hemorrhagic Fever

Symptoms & Phenotypes for Ebola Hemorrhagic Fever

Human phenotypes related to Ebola Hemorrhagic Fever:

60 33 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 60 33 hallmark (90%) Very frequent (99-80%) HP:0012378
2 recurrent pharyngitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0100776
3 nausea and vomiting 60 33 frequent (33%) Frequent (79-30%) HP:0002017
4 abdominal pain 60 33 frequent (33%) Frequent (79-30%) HP:0002027
5 myalgia 60 33 frequent (33%) Frequent (79-30%) HP:0003326
6 chemosis 60 33 frequent (33%) Frequent (79-30%) HP:0012375
7 gastrointestinal hemorrhage 60 33 frequent (33%) Frequent (79-30%) HP:0002239
8 chest pain 60 33 frequent (33%) Frequent (79-30%) HP:0100749
9 diarrhea 60 33 frequent (33%) Frequent (79-30%) HP:0002014
10 cough 60 33 frequent (33%) Frequent (79-30%) HP:0012735
11 headache 60 33 frequent (33%) Frequent (79-30%) HP:0002315
12 cardiac arrest 60 33 frequent (33%) Frequent (79-30%) HP:0001695
13 leukopenia 60 33 frequent (33%) Frequent (79-30%) HP:0001882
14 restrictive ventilatory defect 60 33 frequent (33%) Frequent (79-30%) HP:0002091
15 seizures 60 33 occasional (7.5%) Occasional (29-5%) HP:0001250
16 renal insufficiency 60 33 occasional (7.5%) Occasional (29-5%) HP:0000083
17 proteinuria 60 33 occasional (7.5%) Occasional (29-5%) HP:0000093
18 thrombocytopenia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001873
19 coma 60 33 occasional (7.5%) Occasional (29-5%) HP:0001259
20 epistaxis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000421
21 macule 60 33 occasional (7.5%) Occasional (29-5%) HP:0012733
22 skin rash 60 33 occasional (7.5%) Occasional (29-5%) HP:0000988
23 acute hepatic failure 60 33 occasional (7.5%) Occasional (29-5%) HP:0006554
24 gingival bleeding 60 33 occasional (7.5%) Occasional (29-5%) HP:0000225
25 lethargy 60 33 occasional (7.5%) Occasional (29-5%) HP:0001254
26 metrorrhagia 60 33 occasional (7.5%) Occasional (29-5%) HP:0100608
27 abnormal bleeding 60 Occasional (29-5%)

UMLS symptoms related to Ebola Hemorrhagic Fever:


fever, pruritus

GenomeRNAi Phenotypes related to Ebola Hemorrhagic Fever according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.62 F5 NPC1

Drugs & Therapeutics for Ebola Hemorrhagic Fever

Drugs for Ebola Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
2 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
3
Coal tar Approved Phase 2, Phase 3,Phase 1 8007-45-2
4
Loperamide Approved Phase 2, Phase 3 53179-11-6 3955
5 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
6 polysaccharide-K Phase 3,Phase 2,Phase 1
7 Iron-Dextran Complex Phase 3,Phase 2,Phase 1
8 Anti-Infective Agents Phase 2, Phase 3,Phase 1
9 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
10 Keratolytic Agents Phase 2, Phase 3,Phase 1
11 Dermatologic Agents Phase 2, Phase 3,Phase 1
12
Angiotensin II Approved, Investigational Phase 1, Phase 2 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
13
Atorvastatin Approved Phase 1, Phase 2 134523-00-5 60823
14
Sunitinib Approved, Investigational Phase 1, Phase 2 557795-19-4, 341031-54-7 5329102
15
Irbesartan Approved, Investigational Phase 1, Phase 2 138402-11-6 3749
16
Azithromycin Approved Phase 1, Phase 2 83905-01-5 55185 447043
17
Artemether Approved Phase 2 71963-77-4 119380 68911
18
Lumefantrine Approved Phase 2 82186-77-4 6437380
19 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 1, Phase 2,Phase 2
20 Angiogenesis Modulating Agents Phase 1, Phase 2
21 Angiotensin Receptor Antagonists Phase 1, Phase 2
22 Angiogenesis Inhibitors Phase 1, Phase 2
23 Protein Kinase Inhibitors Phase 1, Phase 2
24
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
25 Hypolipidemic Agents Phase 1, Phase 2,Phase 2
26 Angiotensinogen Phase 1, Phase 2
27 Angiotensin II Type 1 Receptor Blockers Phase 1, Phase 2
28 Antimetabolites Phase 1, Phase 2,Phase 2
29 Antihypertensive Agents Phase 1, Phase 2
30 Giapreza Phase 1, Phase 2
31 Anticholesteremic Agents Phase 1, Phase 2,Phase 2
32 Lipid Regulating Agents Phase 1, Phase 2,Phase 2
33 Antiviral Agents Phase 2,Phase 1
34 Artemether, Lumefantrine Drug Combination Phase 2
35 Vitamins Phase 2
36 Antibiotics, Antitubercular Phase 2,Phase 1
37 Antidiarrheals Phase 2
38 Antibodies Phase 1, Phase 2
39 Immunoglobulins Phase 1, Phase 2
40 Anti-Inflammatory Agents Phase 2
41 Adjuvants, Immunologic Phase 1
42 interferons Phase 1
43 Interferon Inducers Phase 1
44 Radiation-Protective Agents Phase 1
45 Protective Agents Phase 1
46 Antibodies, Monoclonal Phase 1
47 Laxatives Phase 1
48 Cathartics Phase 1
49 Gastrointestinal Agents Phase 1
50 Poly ICLC Phase 1

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi Active, not recruiting NCT03072030 Phase 4
2 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Completed NCT02342171 Phase 2, Phase 3
3 STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) Completed NCT02378753 Phase 2, Phase 3
4 Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine Completed NCT03161366 Phase 3
5 Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) Completed NCT02503202 Phase 3
6 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543268 Phase 3
7 A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543567 Phase 3
8 Investigational Therapeutics for the Treatment of People With Ebola Virus Disease Recruiting NCT03719586 Phase 2, Phase 3 ZMapp;Remdesivir;MAb114;REGN-EB3
9 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Recruiting NCT02661464 Phase 3
10 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Active, not recruiting NCT02509494 Phase 3
11 Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) Withdrawn NCT02307591 Phase 2, Phase 3 Best Supportive Care;Best Supportive Care + Amiodarone
12 Multiple Treatments for Ebola Virus Disease (EVD) Unknown status NCT02380625 Phase 1, Phase 2 Azithromycin;Sunitinib and Erlotinib;Atorvastatin and Irbesartan
13 A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine Completed NCT02575456 Phase 2
14 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults Completed NCT02485301 Phase 2 Placebo
15 Efficacy of Favipiravir Against Ebola (JIKI) Completed NCT02329054 Phase 2 Favipiravir
16 Efficacy of Favipiravir Against Severe Ebola Virus Disease Completed NCT02662855 Phase 2 Favipiravir
17 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children Completed NCT02548078 Phase 2
18 Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults Completed NCT02564523 Phase 2
19 Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo Completed NCT02598388 Phase 2
20 A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland Completed NCT02289027 Phase 1, Phase 2
21 A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-Lyo Completed NCT03333538 Phase 1, Phase 2
22 A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults Completed NCT02416453 Phase 2
23 VSV-ZEBOV Geneva Vaccine Trial Completed NCT02287480 Phase 1, Phase 2
24 Partnership for Research on Ebola VACcinations Recruiting NCT02876328 Phase 2
25 African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola Recruiting NCT03031912 Phase 2
26 GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen Recruiting NCT02818582 Phase 2 GS-5734
27 Yellow Fever Vaccine on Statin/ Non Statin Subjects Recruiting NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
28 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Active, not recruiting NCT02344407 Phase 2
29 Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure Enrolling by invitation NCT02788227 Phase 2
30 Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection Suspended NCT02363322 Phase 1, Phase 2 ZMApp
31 Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen Terminated NCT02739477 Phase 2 Favipiravir
32 An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease Withdrawn NCT02271347 Phase 2 CMX001
33 A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya. Unknown status NCT02296983 Phase 1
34 A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z Unknown status NCT02451891 Phase 1
35 A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults. Completed NCT02326194 Phase 1
36 Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults Completed NCT02718469 Phase 1
37 Evaluating an Ebola and a Marburg Vaccine in Uganda Completed NCT00997607 Phase 1
38 A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo Completed NCT02240875 Phase 1
39 A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization Completed NCT02533791 Phase 1
40 Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda Completed NCT02354404 Phase 1
41 Phase 1 Trial of Ebola Vaccine in Mali Completed NCT02267109 Phase 1
42 Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP) Completed NCT02283099 Phase 1
43 Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects Completed NCT02370589 Phase 1
44 Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine Completed NCT02374385 Phase 1
45 A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China. Completed NCT02401373 Phase 1
46 Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002) Completed NCT02280408 Phase 1
47 A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV Completed NCT02495246 Phase 1
48 Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004) Completed NCT02314923 Phase 1
49 Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001) Completed NCT02269423 Phase 1
50 An Open Study of the Safety and Pharmacokinetics of a Medicinal Product for Emergency Prevention of Ebola Completed NCT03428347 Phase 1

Search NIH Clinical Center for Ebola Hemorrhagic Fever

Cochrane evidence based reviews: hemorrhagic fever, ebola

Genetic Tests for Ebola Hemorrhagic Fever

Anatomical Context for Ebola Hemorrhagic Fever

MalaCards organs/tissues related to Ebola Hemorrhagic Fever:

42
Testes, Eye, Liver, Kidney, Skin, T Cells, Monocytes

Publications for Ebola Hemorrhagic Fever

Articles related to Ebola Hemorrhagic Fever:

(show top 50) (show all 898)
# Title Authors Year
1
Characterization of the plasma proteome of nonhuman primates during Ebola virus disease or melioidosis: a host response comparison. ( 30774579 )
2019
2
Drug Repurposing for Ebola Virus Disease: Principles of Consideration and the Animal Rule. ( 30244014 )
2019
3
Adherence to Universal Travel Screening in the Emergency Department During Epidemic Ebola Virus Disease. ( 30342859 )
2019
4
Immune parameters and outcomes during Ebola virus disease. ( 30626757 )
2019
5
Phylodynamic Analysis of Ebola Virus Disease Transmission in Sierra Leone. ( 30654482 )
2019
6
Children's needs in an Ebola virus disease outbreak. ( 30660206 )
2019
7
Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans1. ( 30666927 )
2019
8
Clinical presentation of pregnant women in isolation units for Ebola virus disease in Sierra Leone, 2014. ( 30706470 )
2019
9
Evidence-Based Clinical Management of Ebola Virus Disease and Epidemic Viral Hemorrhagic Fevers. ( 30712765 )
2019
10
The evolution of supportive care for Ebola virus disease. ( 30732851 )
2019
11
Consensus building around nutrition lessons from the 2014-16 Ebola virus disease outbreak in Guinea and Sierra Leone. ( 30753437 )
2019
12
Ebola virus disease. ( 30777297 )
2019
13
Laboratory findings, compassionate use of favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015 - a retrospective observational study. ( 30788508 )
2019
14
Plasma lipidome reveals critical illness and recovery from human Ebola virus disease. ( 30808769 )
2019
15
Ebola virus disease-related stigma among survivors declined in Liberia over an 18-month, post-outbreak period: An observational cohort study. ( 30811388 )
2019
16
Pre-transfusion testing for Ebola virus disease patients in serious communicable infectious diseases hospitals in Tokyo: A cross-sectional study. ( 30827859 )
2019
17
Modeling the impact of quarantine during an outbreak of Ebola virus disease. ( 30828672 )
2019
18
Development of a screening eye clinic for Ebola virus disease survivors: Lessons learned and rapid implementation at ELWA Hospital in Monrovia, Liberia 2015. ( 30845141 )
2019
19
The Ebola virus disease outbreak in Tonkolili district, Sierra Leone: a retrospective analysis of the Viral Haemorrhagic Fever surveillance system, July 2014-June 2015. ( 30869055 )
2019
20
Ebola virus disease and palliative care in humanitarian crises. ( 30894269 )
2019
21
Recent advances in the development and evaluation of molecular diagnostics for Ebola virus disease. ( 30916590 )
2019
22
Molecular detection of dengue virus in patients suspected of Ebola virus disease in Ghana. ( 30566466 )
2018
23
Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein. ( 30095362 )
2018
24
Clinical Manifestations and Pathogenesis of Uveitis in Ebola Virus Disease Survivors. ( 29993303 )
2018
25
Modeling ebola virus disease transmissions with reservoir in a complex virus life ecology. ( 29161826 )
2018
26
The French Infectious Diseases Society's readiness and response to epidemic or biological risk-the current situation following the Middle East respiratory syndrome coronavirus and Ebola virus disease alerts. ( 29169817 )
2018
27
Regulatory and Operational Complexities of Conducting a Clinical Treatment Trial During an Ebola Virus Disease Epidemic. ( 29206908 )
2018
28
Ebola virus disease: Biological and diagnostic evolution from 2014 to 2017. ( 29224715 )
2018
29
Emergence of Vaccine-Derived Polioviruses during Ebola Virus Disease Outbreak, Guinea, 2014-2015. ( 29260690 )
2018
30
Management of Ebola Virus Disease in Children. ( 29269191 )
2018
31
Clinical Laboratory Values in Human Ebola Virus Disease Support the Relevance of the Intramuscular Ebola-Kikwit Rhesus Model. ( 29272400 )
2018
32
Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease. ( 29281112 )
2018
33
Initiation and publication time-lags of treatment trials for Ebola virus disease. ( 29303737 )
2018
34
Establishing Ebola Virus Disease (EVD) diagnostics using GeneXpert technology at a mobile laboratory in Liberia: Impact on outbreak response, case management and laboratory systems strengthening. ( 29304039 )
2018
35
Histology, immunohistochemistry, and in situ hybridization reveal overlooked Ebola virus target tissues in the Ebola virus disease guinea pig model. ( 29352230 )
2018
36
Clinical Manifestations and Modes of Death among Patients with Ebola Virus Disease, Monrovia, Liberia, 2014. ( 29405115 )
2018
37
Active Monitoring of Travelers for Ebola Virus Disease-New York City, October 25, 2014-December 29, 2015. ( 29406796 )
2018
38
Unintended consequences of the 'bushmeat ban' in West Africa during the 2013-2016 Ebola virus disease epidemic. ( 29421463 )
2018
39
Ebola Virus Localization in the Macaque Reproductive Tract during Acute Ebola Virus Disease. ( 29429544 )
2018
40
The impact of the 2014 Ebola virus disease outbreak in Liberia on parent preferences for harsh discipline practices: a quasi-experimental, pre-post design. ( 29435351 )
2018
41
Re: Shantha et al.: Ophthalmic manifestations and causes of vision impairment in Ebola virus disease survivors in Monrovia, Liberia (Ophthalmology. 2017;124:170-177). ( 29458832 )
2018
42
The 2014-2015 Ebola virus disease outbreak and primary healthcare delivery in Liberia: Time-series analyses for 2010-2016. ( 29462138 )
2018
43
Incorporating health workers' perspectives into a WHO guideline on personal protective equipment developed during an Ebola virus disease outbreak. ( 29527297 )
2018
44
Food Insecurity as a Risk Factor for Outcomes Related to Ebola Virus Disease in Kono District, Sierra Leone: A Cross-Sectional Study. ( 29557329 )
2018
45
Knowledge, attitude and practice of medical laboratory practitioners in the fight against Ebola virus disease. ( 29568545 )
2018
46
Maternal and perinatal outcomes in pregnant women with suspected Ebola virus disease in Sierra Leone, 2014. ( 29569244 )
2018
47
Post-exposure prophylaxis in Ebola virus disease: don't forget the psychological factors. ( 29582761 )
2018
48
Field investigation with real-time virus genetic characterisation support of a cluster of Ebola virus disease cases in Dubréka, Guinea, April to June 2015. ( 29589579 )
2018
49
The Impact of a Case of Ebola Virus Disease on Emergency Department Visits in Metropolitan Dallas-Fort Worth, TX, July, 2013-July, 2015: An Interrupted Time Series Analysis. ( 29623242 )
2018
50
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. ( 29627147 )
2018

Variations for Ebola Hemorrhagic Fever

Expression for Ebola Hemorrhagic Fever

Search GEO for disease gene expression data for Ebola Hemorrhagic Fever.

Pathways for Ebola Hemorrhagic Fever

GO Terms for Ebola Hemorrhagic Fever

Biological processes related to Ebola Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to virus GO:0009615 8.62 BST2 DDX58

Sources for Ebola Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....